Photocure partner asieris unveils cevira (apl-1702) phase iii subgroup analysis by age groups at the 2024 csco annual meeting

Oslo, norway , sept. 30, 2024 /prnewswire/ -- photocure asa (ose: pho), the bladder cancer company, announces that its partner asieris pharmaceuticals (sse: 688176) communicated that international multicenter phase iii clinical study data for its non-surgical treatment candidate cevira® (apl-1702) for cervical high-grade squamous intraepithelial lesion (hsil) has been published by the 27th chinese society of clinical oncology (csco) annual meeting as a poster, focusing on the analysis of different age subgroups regarding the six-month pathological regression rate and hpv clearance rate.
CSCO Ratings Summary
CSCO Quant Ranking